Oncology News | pharmaphorum

News

Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.

News

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and Black women.

News

Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.

News

Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.